Czynnik wzrostu fibroblastów 21 i jego związek z wrażliwością na insulinę u krewnych pierwszego stopnia chorych na cukrzycę typu 2

  Introduction: Fibroblast growth factor 21 (FGF 21) has been suggested as a predictor for the development of type 2 diabetes mellitus (T2DM). Material and methods: We aimed to determine FGF 21 levels in normoglycaemic (Group 1) and prediabetic (Group 2) first-degree relatives (FDR) of patients with T2DM in comparison with normoglycaemic subjects without a history of T2DM in their FDR (Group 3). Results: There was a significant difference between Group 1, 2, and 3 with respect to plasma FGF 21 concentrations (143.3 ± 93.8, 221.9 ± ± 171.7 and 121.2 ± 119.8 pg/mL, respectively, p = 0.01). FGF 21 levels were significantly increased in prediabetic FDR of patients with T2DM compared to normoglycaemic subjects without a history of T2DM in their FDR (p = 0.02). FGF 21 levels did not differ between normoglycaemic FDR of patients with T2DM and normoglycaemic subjects without a history of T2DM in their FDR (p > 0.05). In the whole group, FGF 21 correlated positively with age (r = 0.31, p = 0.003), BMI (r = 0.38, p < 0.001), systolic blood pressure (r = 0.38, p = 0.001), diastolic blood pressure (r = 0.26, p = 0.02), fasting blood glucose (r = 0.24, p = 0.02), HOMA-IR (r = 0.23, p = 0.03), AUC glucose (r = 0.35, p = 0.001), and AUC insulin (r = 0.32, p = 0.003) and negatively with HDL cholesterol (r = –0.24, p = 0.02) and Matsuda ISI (r = –0.33, p = 0.002). In the regression analysis, BMI was the most predictive factor for FGF 21 levels (beta = 0.41, r2 = 0.17, p < 0.001). Conclusions: We showed that FGF 21 concentrations are increased in prediabetic FDR of patients with T2DM and that there is a significant association between FGF 21 and obesity and insulin sensitivity. (Endokrynol Pol 2016; 67 (3): 260–264)    Wstęp: Sugerowano, że stężenie czynnika wzrostu fibroblastów 21 (FGF 21) jest czynnikiem predykcyjnym rozwoju cukrzycy typu 2 (T2DM). Materiał i metody: Celem badania było ustalenie stężenia FGF 21 u osób z normoglikemią (grupa 1) i ze stanem przedcukrzycowym (grupa 2) będących krewnymi pierwszego stopnia (FDR) chorych na T2DM w porównaniu z osobami z normoglikemią z ujemnym wywiadem rodzinnym w kierunku T2DM (grupa 3). Wyniki: Stwierdzono istotne różnice między grupami 1, 2 i 3 pod względem stężenia FGF 21 w osoczu (odpowiednio 143,3 ± 93,8; 221,9 ± 171,7 i 121,2 ± 119,8 pg/ml; p = 0,01). Stężenia FGF 21 były istotnie wyższe w grupie krewnych pierwszego stopnia chorych na T2DM ze stanem przedcukrzycowym niż u osób z normoglikemią bez dodatniego wywiadu rodzinnego w kierunku T2DM (p = 0,02). Stężenia FGF 21 nie różniły się istotnie między krewnymi pierwszego stopnia chorych na T2DM z normoglikemią a osobami z normoglikemią bez T2DM u krewnych pierwszego stopnia (p > 0,05). W całej badanej grupie stwierdzono dodatnią korelację między stężeniem FGF 21 a wiekiem (r = 0,31; p = 0,003), BMI (r = 0,38; p < 0,001), skurczowym ciśnieniem tętniczym (r = 0,38; p = 0,001), rozkurczowym ciśnieniem tętniczym (r = 0,26; p = 0,02), glikemią na czczo (r = 0,24; p = 0,02), wskaźnikiem HOMA-IR (r = 0,23; p = 0,03), AUC glukozy (r = 0,35; p = 0,001), AUC insuliny (r = 0,32; p = 0,003) oraz ujemną korelację ze stężeniem cholesterolu frakcji HDL (r = –0,24; p = 0,02) i wskaźnikiem ISI według Matsudy (r = –0,33; p = 0,002). W analizie regresji najsilniejszym czynnikiem prognostycznym stężenia FGF 21 był wskaźnik BMI (beta = 0,41; r2 = 0,17; p < 0,001). Wnioski: Podsumowując, autorzy wykazali, że stężenia FGF 21 są zwiększone u krewnych pierwszego stopnia chorych na T2DM ze stanem przedcukrzycowym i że istnieje silny związek między stężeniem FGF 21 a otyłością i wrażliwością na insulinę. (Endokrynol Pol 2016; 67 (3): 260–264)

Cytologic comparison between growing and non-growing benign thyroid nodules evaluated using two different growth criteria

Amaç: Tiroid nodülü erişkinlerde sık görülür. Tiroid nodülünün klinik olarak en büyük önemi %5-10 oranında kanser varlığıdır. Tiroid ince iğne aspirasyon biyopsisi tiroid nodülünün kanser varlığını araştırmak amaçlı ilk tercih edilen yöntemdir. Biyopsi ile benign oldukları saptanan nodüllerin klinik olarak izlenmesi, büyüme tespit edildiğinde yeniden biyopsi alınması önerilmektedir. Fakat net bir büyüme kriteri belirlenmemiştir. Farklı büyüme kriterleri kullanılarak yapılan çalışmalarda büyüyen nodüllerde kanser için anlamlı bir risk artışı saptanmamıştır. Yöntem: Dokuz Eylül Üniversitesi Hastanesi'nde Ocak 2006 - Haziran 2009 tarihleri arasında uygulanan TİİAB kayıtları geriye dönük olarak incelendi. İkinci bir TİİAB yapılmış olan benign nodüllerin izlemdeki büyümeleri iki farklı büyüme kriteri kullanılarak (en büyük nodül çapında %50 ve ya üzerinde artış, nodülün en az iki çapında -2 mm'den az olmamak üzere- %20 ve ya üzerinde artış) değerlendirildi. Büyüyenlerle büyümeyenlerin sitolojik sonuçları iki farklı kritere göre ayrı ayrı karşılaştırıldı. Bulgular: İnce iğne aspirasyon biyopsisi yapılan 4217 tiroid nodülden izlem biyopsileri olan benign nodüller incelemeye alındı. İzlemde maximum çapta %50 ve üzerinde artışa göre büyüyenle (n: 43), bu kritere göre büyümeyen (n:136) benign nodüller incelendiğinde aralarında anlamlı sitolojik fark saptanmadı(p:1,00). Benzer şekilde nodülün en az iki çapında -iki mm'den az olmamak üzere %20 ve üzerinde boyut artışı saptanan nodüllerle (n:47), bu kritere göre büyümeyenler (n:70) arasında anlamlı sitolojik fark saptanmadı(p:0,70). Sonuç: Çalışmada kullanılan iki farklı büyüme kriterine göre benign nodüllerin izlemde büyümesi kanser varlığı için ek risk oluşturmamıştır. Anahtar Kelimeler: Tiroid nodülü, Büyüme, Tiroid İnce İğne Aspirasyon Biyopsisi Aim: Thyroid nodules are frequent in the adult population. They are clinically important because of 5-10% risk of cancer. Thyroid fine needle aspiration biopsy is the first choice for diagnosing cancer in the nodule. It is suggested that biopsy-proven benign thyroid nodules should be followed up clinically and if they grow, re-biopsy should be performed. However, certain growth criteria have not been defined yet. In many studies using different growth criteria, significant risk for cancer in growing thyroid nodules was not demonstrated. Method: We retrospectively reviewed thyroid fine needle aspiration records of all patients seen in Dokuz Eylül University Hospital between January 2006 and June 2009. Growth follow-up of the nodules which had second thyroid fine needle aspiration biopsy were evaluted using two different growth criteria (at least 50% increase in nodule maximal diameter and at least 20% increase in nodule diameter with a minimum increase in two or more dimensions of at least two milimeter). Cytologic results were compared using two different criteria. Results: From a total of 4217 thyroid nodules, we evaluated the cytologic results of the benign thyroid nodüles which had follow up biyopsies. There is no significant difference in cytological results between the growing group (n:43) which have at least 50% increase in maximal nodule diameter and the non growing group (n:136)(p:1,00). Likewise, using the growth criteria of at least 20% increase in nodule diameter with a minimum increase in two or more dimensions of at least two milimeter, there was no significant difference in cytological results between growing (n:47) and non growing (n:70) benign thyroid nodüles(p:0,7). Conclusion: According to two different growth criteria used in our study, growth of a benign nodule is not an additional risk factor for cancer. Key words: Tyroid nodule, growth, thyroid fine needle aspiration biyopsy

Synthesis, molecular structure and spectroscopic characterization of (E)-1-((2-hydroxynaphthalen-1-y1) methyleneamino)-5-(4-methoxybenzoy1)-4-(4-methoxyphenyl) pyrimidine-2(1H)-one with experimental techniques and theoretical calculations

Aygun, Muhittin/0000-0001-9670-9062; Aygun, Muhittin/0000-0001-9670-9062; ceylan, umit/0000-0002-1461-9889WOS: 000378100700026A new Schiff base compound, (E)-1((2-hydroxynaphthalen-l-y1) methyleneamino)-5-(4-methoxybenzoy1)-4-(4-methoxyphenyl) pyrimidine-2(1H)-one, formula sum is given by C30H23N3O5, was synthesized and characterized by experimentally and theoretically. Optimized molecular structure was obtained using X-ray diffraction in the ground state. FT-IR, NMR and UV-Vis frequencies have been measured and compared with theoretically obtained data by using by DET/B3LYP method with 6-31G(d) and 6-311++G(d,p) basis set In addition, molecular electrostatic potential (MEP), dipole moments, NBO analysis, atomic charges, HOMO-LUMO and molecular electrostatic potential were computed. The calculated results show that the optimized geometry can well reproduce the crystal structure parameters, and the theoretical vibrational frequencies, H-1 and C-13 NMR chemical shifts show good agreement with experimental values. (C) 2016 Elsevier B.V. All rights reserved

Vibrational spectroscopic and thermo dynamical property studies, Fukui functions, HOMO-LUMO, NLO, NBO and crystal structure analysis of a new Schiff base bearing phenoxy-imine group

Aygun, Muhittin/0000-0001-9670-9062; Aygun, Muhittin/0000-0001-9670-9062; ceylan, umit/0000-0002-1461-9889WOS: 000397375800023This study covers the synthesis, structural characterization by experimental FT-IR, H-1 NMR and C-13 NMR, UV-Vis and single crystal XRD and comparison with theoretical calculations of a Schiff base compound bearing phenoxy group, C34H28N2O4 by using the DFT method 6-311G(d,p) basis set. The molecular geometry, the dipole moments, electrostatic potential, vibrational frequencies, HOMO-LUMO energy were calculated. NBO, NLO, thermodynamic properties and Fukui function were studied. In this work, theoretical values show good agreement with experimental values. (C) 2017 Elsevier B.V. All rights reserved.chairmanship of Scientific Research Projects of Gaziantep University [FEF.10.08]This project has been funded by chairmanship of Scientific Research Projects of Gaziantep University (FEF.10.08). The authors thank Dokuz Eylill University for single crystal XRD measurement

Eu(III) and Tb(III) complexes of 1,3-bis(4-chlorophenyl)-1,3-propanedione combined with phenanthroline ligand: synthesis, structural characterization, and thermogravimetric studies

WOS: 000464620100001-Diketone lanthanide complexes are used mainly in lighting, telecommunication, screens, safety inks, and marking as well as in the field of luminescent materials for probes in biosciences. Two new lanthanide ternary complexes, the general formula Eu(BCPP)(3)(Phen) and Tb(BCPP)(3)(Phen), combined 1,3-bis(4-chlorophenyl)-1,3-propanedione (BCPP) with 1,10-phenanthroline as a secondary ligand, were synthesized and structurally characterized by single crystal X-ray diffraction, elemental analysis, FT-IR, and MALDI-TOF MS. Single crystal X-ray diffraction analysis revealed that these Eu(III) and Tb(III) complexes displayed bidentate ligands and a square antiprism geometry for the metal center. Also, the absorption and thermal behavior of these lanthanide complexes were investigated. When the maximum absorption of the lanthanide complexes was compared, it was observed that the absorption wavelength of the lanthanide complexes were red shifted in DMSO, DMF, and DCM, depending on the polarity of the solvent.TuBTAKTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [115Z840]; Giresun UniversityGiresun University [FEN-BAP-A-140316-57]1 The authors thank TuBTAK (Project no: 115Z840) and Giresun University (FEN-BAP-A-140316-57) for the financial support